Pioglitazone ameliorates endothelial dysfunction in those with impaired glucose regulation among the first-degree relatives of type 2 diabetes mellitus patients

Medical Principles and Practice

Volumn 22, Issue 2, 2013, Pages 156-160

  Yu, Xuemei ^a   Chen, Peihong ^a   Wang, Hongtao ^a   Zhu, Tong ^a  

^a Fengxian Central Hospital   (China)

Author keywords

Endothelial dysfunction; Impaired glucose regulation; Pioglitazone

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ENDOCRINE FUNCTION TEST; ENDOTHELIAL DYSFUNCTION; EXERCISE; FEMALE; FIRST DEGREE RELATIVE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE REGULATION; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION;

EID: 84873713050     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000341770     Document Type: Article

References (21)

1. Caballero AC. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003; 11: 1278-1289.
2. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Häring HU. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-1784.
3. DREAM Trial Investigators, Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, et al: Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008; 31: 1007-1014.
4. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, et al: ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364: 1104-1115.
5. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27: 484-490.
6. Celermajer DS, Sorensen KE, Gooch VW, Sullivan ID, Lloyd JK, Deanfield JE, Spiegelhalter DJ. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
7. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
8. American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases: Prevention or delay of type 2 diabetes. Diabetes Care 2004; 27:s47-s54.
9. Brame L, Verma S, Anderson T. Insulin resistance as a target for improved endothelial function: metformin. Curr Drug Targets Cardiovasc Haematol 2004; 4: 53-63.
10. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-1904.
11. Saydah SH, Loria CM, Eberhardt MS, Frederick L. Subclinical states of glucose intolerance and risk of death in the U. S. Diabetes Care 2001; 24: 447-453.
12. Bjornholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, Erikssen J, Thaulow E. Fasting blood glucose: an underestimated risk factor for cardiovascular death: results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 1999; 22: 45-49.
13. Baykan M, Erem C, Gedikli O, Hacihasanoglu A, Erdogan T, Kocak M, Kaplan S, Korkmaz L, Celik S. Impairment in flow-mediated vasodilatation of the brachial artery in acromegaly. Med Princ Pract 2009; 18: 228-232.
14. Zhang H, Dellsperger KC, Zhang C. The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update. Basic Res Cardiol 2012; 107: 237.
15. Rizza S, Cardellini M, Porzio O, Pecchioli C, Savo A, Cardolini I, Senese N, Lauro D, Sbraccia P, Lauro R, Federici M. Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. Atherosclerosis 2011; 215: 180-183.
16. Quinn CE, Lockhart CJ, Hamilton PK, Loughrey CM, McVeigh GE. Effect of pioglitazone on endothelial function in impaired glucose tolerance. Diabetes Obes Metab 2010; 12: 709-715.
17. Hidaka T, Nakagawa K, Goto C, Soga J, Fujii Y, Hata T, Idei N, Fujimura N, Chayama K, Kihara Y, Higashi Y. Pioglitazone improves endothelium-dependent vasodilation in hypertensive patients with impaired glucose tolerance in part through a decrease in oxidative stress. Atherosclerosis 2010; 210: 521-524.
18. Li F, Zhao T, Wen X. Changes in serum adiponectin concentrations and endothelial function after intensive insulin treatment in people with newly diagnosed type 2 diabetes: a pilot study. Diabetes Res Clin Pract 2011; 94: 186-192.
19. Naka KK, Papathanassiou K, Bechlioulis A, Pappas K, Kazakos N, Kanioglou C, Kostoula A, Vezyraki P, Makriyiannis D, Tsatsoulis A, Michalis LK. Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas. Diab Vasc Dis Res 2012; 9: 52-58.
20. Papathanassiou K, Naka KK, Kazakos N, Kanioglou C, Makriyiannis D, Pappas K, Katsouras CS, Liveris K, Kolettis T, Tsatsoulis A, Michalis LK. Pioglitazone vs glimepiride: differential effects on vascular endothelial function in patients with type 2 diabetes. Atherosclerosis 2009; 205: 221-226.
21. Chan DC, Wong AT, Yamashita S, Watts GF. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment. Atherosclerosis 2012; 221: 484-489.